Aurelia Morabito

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Aurelia Morabito is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

6 Article

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial: Journal of Thoracic Oncology
Piccirillo, M. C., Bonanno, L., Garassino, M. C., Esposito, G., Dazzi, C., Cavanna, L., Burgio, M. A., Rosetti, F., Rizzato, S., Morgillo, F., Cinieri, S., Veccia, A., Papi, M., Tonini, G., Gebbia, V., Ricciardi, S., Pozzessere, D., Ferro, A., Proto, C., Costanzo, R., & 13 othersD'Arcangelo, M., Proietto, M., Gargiulo, P., Di Liello, R., Arenare, L., De Marinis, F., Crinò, L., Ciardiello, F., Normanno, N., Gallo, C., Perrone, F., Gridelli, C. & Morabito, A., 2022, In: J. Thorac. Oncol.. 17, 9, p. 1086-1097 12 p.
Research output: Contribution to journal › Article › peer-review
Corrigendum: “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”: [Annals of Oncology 33 (2022) 57-66]: Annals of Oncology
Novello, S., Torri, V., Grohe, C., Kurz, S., Serke, M., Wehler, T., Meyer, A., Ladage, D., Geissler, M., Colantonio, I., Cauchi, C., Stoelben, E., Ceribelli, A., Kropf-Sanchen, C., Valmadre, G., Borra, G., Schena, M., Morabito, A., Santo, A., Gregorc, V., & 16 othersChiari, R., Reck, M., Schmid-Bindert, G., Folprecht, G., Griesinger, F., Follador, A., Pedrazzoli, P., Bearz, A., Caffo, O., Dickgreber, N. J., Irtelli, L., Wiest, G., Monica, V., Porcu, L., Manegold, C. & Scagliotti, G. V., 2022, In: Ann. Oncol..
Research output: Contribution to journal › Article › peer-review
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
Cantini, L., Mentrasti, G., Russo, G. L., Signorelli, D., Pasello, G., Rijavec, E., Russano, M., Antonuzzo, L., Rocco, D., Giusti, R., Adamo, V., Genova, C., Tuzi, A., Morabito, A., Gori, S., Verde, N. L., Chiari, R., Cortellini, A., Cognigni, V., Pecci, F., & 42 othersIndini, A., De Toma, A., Zattarin, E., Oresti, S., Pizzutilo, E. G., Frega, S., Erbetta, E., Galletti, A., Citarella, F., Fancelli, S., Caliman, E., Della Gravara, L., Malapelle, U., Filetti, M., Piras, M., Toscano, G., Zullo, L., De Tursi, M., Di Marino, P., D'Emilio, V., Cona, M. S., Guida, A., Caglio, A., Salerno, F., Spinelli, G., Bennati, C., Morgillo, F., Russo, A., Dellepiane, C., Vallini, I., Sforza, V., Inno, A., Rastelli, F., Tassi, V., Nicolardi, L., Pensieri, V., Emili, R., Roca, E., Migliore, A., Galassi, T., Rocchi, M. L. B. & Berardi, R., 2022, In: ESMO Open. 7, 2, 100406.
Research output: Contribution to journal › Article › peer-review
Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement: Digestive and Liver Disease
Urso, E. D. L., Ponz de Leon, M., Vitellaro, M., Piozzi, G. N., Bao, Q. R., Martayan, A., Remo, A., Stigliano, V., Oliani, C., Lucci Cordisco, E., Pucciarelli, S., Ranzani, G. N., Viel, A., Adami, F., Alducci, E., Amadori, L., Arcangeli, V., Balestrino, L., Barana, D., Bertario, L., & 58 othersBonanni, B., Boni, S., Bullian, P., Carbonardi, F., Carnevali, I., Castelli, P., Celotto, F., Cini, G., Crivellari, G., Libera, D. D., Dell'elice, A., Digennaro, M., D'urso, A., Fabretto, A., Fanale, D., Feroce, I., Furlan, D., Ghiorzo, P., Giacché, M., Gusella, M., Liserre, B., Mammi, I., Massuras, S., Mazzà, D., Mollica, E., Morabito, A., Nardo, G., Palermo, F., Panizza, E., Patruno, M., Pedroni, M., Pensotti, V. G. M., Pozzi, S., Presi, S., Puzzono, M., Ravegnani, M., Ricci, M. T., Roncucci, L., Rossi, G. B., Sala, E. M., Mete, L. S., Sandonà, D., Sciallero, S., Serrano, D., Signoroni, S., Spina, F., Taborelli, M., Tedaldi, G., Tibiletti, M. G., Tognazzo, S., Tolva, G., Trovato, C. M. C., Turchetti, D., Varvara, D., Vivanet, C., Zovato, S., Zuppardo, R. A. & group, AIFEG., 2021, In: Dig. Liver Dis..
Research output: Contribution to journal › Article › peer-review
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial
Cascinu, S., Berardi, R., Bianco, R., Bilancia, D., Zaniboni, A., Ferrari, D., Mosconi, S., Spallanzani, A., Cavanna, L., Leo, S., Negri, F., Beretta, G. D., Sobrero, A., Banzi, M., Morabito, A., Bittoni, A., Marciano, R., Ferrara, D., Noventa, S., Piccirillo, M. C., & 5 othersLabianca, R., Mosconi, C., Casadei Gardini, A., Gallo, C. & Perrone, F., May 2021, In: European Journal of Cancer. 148, p. 422-429 8 p.
Research output: Contribution to journal › Article › peer-review

Aurelia Morabito

Fingerprint

Research output

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial: Journal of Thoracic Oncology

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement: Digestive and Liver Disease

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial